LTBI: latent tuberculosis infection or lasting immune responses to M. tuberculosis? A TBNET consensus statement

By U. Mack, G. Migliori, M. Sester, H. Rieder, S. Ehlers, D. Goletti, A. Bossink, K. Magdorf, C. Hölscher, B. Kampmann and 13 more. European Respiratory Journal, 2009

639 citations recorded by the source corpus.

Subfields: Infectious Diseases, Surgery

View Paper: https://www.semanticscholar.org/paper/100935346f5690408bcc950a3332cd4c5f6b7c3f

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Infectious Diseases

1. A. O’Garra
2. Madhukar Pai
3. R. Wilkinson
4. A. Zwerling
5. M. Berry
6. Finlay W Mcnab
7. Paul S. Redford
8. C. Bloom

In Surgery

1. A. O’Garra
2. Madhukar Pai
3. R. Wilkinson
4. A. Zwerling
5. M. Berry
6. Finlay W Mcnab
7. Paul S. Redford
8. C. Bloom

Citations in the corpus

• Gamma Interferon Release Assays for Detection of Mycobacterium tuberculosis Infection (2014, background): “For all these reasons, both TST and IGRAs are generally unable to select out the phenotypes that are most likely to benefit from LTBI treatment (88, 130).”
• The immune response in tuberculosis. (2013, background): “The heterogeneity within the latent TB population is gaining more widespread acceptance (18) and highlights the need for diagnostic tools that differentiate the full spectrum of these diverse responses to infection (18, 49, 68).”